
In this episode of Denatured, as part of our series on the European life sciences investment ecosystem, you'll hear from Hannah Franklin, associate at Biovance Capital and Pablo Gabriel Cironi Lopez, director of life science investment at Caixa Capital Risc. We examine the rise of Southern Europe’s biotech ecosystem—from Portugal’s efforts to turn strong science into startups to Spain’s growing depth of capital and talent—and what it will take for the region to compete globally.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsHannah Franklin, Associate, Biovance CapitalPablo Gabriel Cironi Lopez, Director, Life Science Investment, Caixa Capital RiscDisclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Rethinking hair loss treatment

ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck

France’s biotech ecosystem: science, capital and scale
Free AI-powered recaps of BioSpace and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.